Who is sponsoring NCT04727723?

NCT04727723 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT04727723?

Interventions in NCT04727723: Lutathera®.

What condition does NCT04727723 study?

NCT04727723 studies Gastroenteropancreatic Neuroendocrine Tumor.

Is NCT04727723 still recruiting?

NCT04727723 is currently active, enrolled. Last updated 20 March 2026.

Last reviewed 2026-03-20 · How we verify

NCT04727723: REAL-LU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Active, enrolled Last updated 20 March 2026

What this trial tests

trial testing Lutathera® in Gastroenteropancreatic Neuroendocrine Tumor in 164 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 March 2021

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	164
Start date	9 March 2021
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	18 locations across Italy

Drugs / interventions tested

Lutathera®

Conditions studied

Gastroenteropancreatic Neuroendocrine Tumor — all drugs for Gastroenteropancreatic Neuroendocrine Tumor →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Gastroenteropancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

[<sup>177</sup>Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective.
Spada F, Campana D, Lamberti G, Laudicella R, et al · · 2022 · cited 11× · PMID 34950969 · DOI 10.1007/s00259-021-05656-x
An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis.
Yan H, Zhang JL, Leung KT, Lo KW, et al · · 2023 · cited 8× · PMID 36765694 · DOI 10.3390/cancers15030736
The road to overcome pancreatic cancer: Where are we?
Tirpe A, Streianu C, Isachesku E, Simon I, et al · · 2024 · cited 6× · PMID 39403527 · DOI 10.1016/j.heliyon.2024.e38196
Lutetium [<sup>177</sup>Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study.
Lastoria S, Rodari M, Sansovini M, Baldari S, et al · · 2024 · cited 4× · PMID 38772998 · DOI 10.1007/s00259-024-06725-7

Verify or expand the search:

Other recruiting trials for Gastroenteropancreatic Neuroendocrine Tumor

Currently open trials in the same condition.

NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
NCT06256705 — Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionucl · NA · recruiting
NCT05636618 — Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors · Phase 1, PHASE2 · recruiting
NCT06155318 — 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04727723 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 20 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04727723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing